Karyopharm Therapeutics Inc
(NAS:KPTI)
$
0.6763
-0.0238 (-3.4%)
Market Cap: 85.34 Mil
Enterprise Value: 149.08 Mil
PE Ratio: 0
PB Ratio: 0
GF Score: 68/100 Karyopharm Therapeutics Inc at Jefferies London Healthcare Conference (Virtual) - On-Demand Transcript
Nov 18, 2021 / 08:00AM GMT
Release Date Price:
$8.24
(-0.60%)
Maurice Thomas Raycroft
Jefferies LLC, Research Division - Equity Analyst
Hi, everyone. My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. It's with great pleasure that I'd like to welcome the Karyopharm team, including Richard Paulson, CEO; Mike Mason, CFO; and Jatin Shah, the CMO. Thanks for joining us today for our London conference.
Richard A. Paulson
Karyopharm Therapeutics Inc. - President, CEO & Director
Absolutely. Great to be here, Maury.
Questions & Answers
Maurice Thomas Raycroft
Jefferies LLC, Research Division - Equity Analyst
And we're going to do a fireside chat format. So maybe to start off, for those who may be new to the story, can you provide a 1-minute intro to Karyopharm?
Richard A. Paulson
Karyopharm Therapeutics Inc. - President, CEO & Director
Sure. I mean when you look at Karyopharm, we're still a young company. We are an innovation and science-based commercial-stage pharmaceutical company now that
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot